Drugs in R & D

, Volume 3, Issue 4, pp 258–270 | Cite as

Gemifloxacin

Factive, LB 20304, SB 265805
Adis R&D Profile

Keywords

Omeprazole Clarithromycin Ofloxacin Levofloxacin Chronic Bronchitis 

References

  1. 1.
    GlaxoSmithKline, LG Chemical Investments. LG Chemical Investments to regain worldwide rights to commercialize gemifloxacin. Media Release: 15 Apr 2002 Available from: URL: http://www.gsk.com Google Scholar
  2. 2.
    SmithKline Beecham. SmithKline Beecham receives nonapproval letter from the FDA on Factive (R). Media Release [1 page], 15 Dec 2000. Available from: URL http://www.sb.com Google Scholar
  3. 3.
    Ramji JV, Boyle GW, Chalker MH, Collins G, Duncan G, et al. The metabolism of [14C]gemifloxacin in rat, dog and man. Drug Metabolism Reviews 32 (Suppl 2): 268, 2000Google Scholar
  4. 4.
    Allen A, Bygate E, Teillol-Foo M, Oliver SD, Johnson M, et al. Multiple-dose pharmacokinetics and tolerability of gemifloxacin following oral doses to healthy volunteers. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 133 (plus poster), Jul 1999Google Scholar
  5. 5.
    Pay V, Allen A, Bygate E, Paanakker L, Montague T. Multipledose pharmacokinetics and tolerability of gemifloxacin following once-daily repeat oral 320mg doses to healthy elderly volunteers. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 38 (plus poster), 17 Sep 2000Google Scholar
  6. 6.
    Davy M, Allen A, Bird N, Romain D. Pharmacokinetics and tolerability of gemfloxacin in healthy Japanese and Caucasian volunteers. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 37 (plus poster), 17 Sep 2000Google Scholar
  7. 7.
    Allen A, Bygate E, Clark D, Lewis A, Pay V. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. International Journal of Antimicrobial Agents 16: 45–50, Sep 2000PubMedCrossRefGoogle Scholar
  8. 8.
    Sidhu J, Bullman J, Taylor A, Smith A, Allen A, et al. Phase III population pharmacokinetics of gemifloxacin. 7th World Conference on Clinical Pharmacology and Therapeutics (CPT) and the 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) 227, 15 Jul 2000Google Scholar
  9. 9.
    Vousden M, Ferguson J, Richards J, Bird N, Allen A. Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. Chemotherapy (Basel) 45: 512–520, Nov–Dec 1999Google Scholar
  10. 10.
    Henkel TJ, McKay D, Young C. Safety of gemfloxacin in patients aged greater than or equal to 65 years with respiratory and urinary tract infections. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 475 (plus poster), 17 Sep 2000Google Scholar
  11. 11.
    Bird N, Lewis A, Montague T, Bygate E, Dixon R. Assessment of the effect of gemifloxacin on QTc interval in healthy volunteers. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 477 (plus poster), 17 Sep 2000Google Scholar
  12. 12.
    Ball P, Wilson R, Mandell L, et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomised, double-blind comparison with trovafloxacin. Journal of Chemotherapy 13: 288–298, Jun 2001PubMedGoogle Scholar
  13. 13.
    Lowe MN, Lamb HM. Gemifloxacin. Drugs 59: 1137–1147, May 2000PubMedCrossRefGoogle Scholar
  14. 14.
    Wilson R, Ball P, Mandell L, File T, 068 Clinical Study Group, et al. Efficacy of once daily gemifloxacin for 5 days compared with twice daily clarithromycin for 7 days in the treatment of AECB. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 476 (plus poster), 17 Sep 2000Google Scholar
  15. 15.
    File T, Schlemmer B, Garau J, Lode H, 070 Clinical Study Group, et al. Gemifloxacin versus amoxicillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Journal of Chemotherapy 12: 314–325, Aug 2000PubMedGoogle Scholar
  16. 16.
    Vousden M, Allen A, Lewis A, Rauland M, Ehren N. Lack of effect of gemifloxacin on the pharmacokinetics of steady-state digoxin in healthy elderly volunteers. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 138 (plus poster), Jul 1999Google Scholar
  17. 17.
    Vousden M, Allen A, Lewis A, Ehren N. Lack of pharmacokinetic interaction between gemifloxacin and digoxin in healthy elderly volunteers. Chemotherapy (Basel) 45: 485–490, Nov–Dec 1999Google Scholar
  18. 18.
    Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 132–133 (plus poster), Jul 1999Google Scholar
  19. 19.
    Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. Chemotherapy (Basel) 45: 491–495, Nov–Dec 1999Google Scholar
  20. 20.
    Allen A, Vousden M, Porter A, Lewis A, Teillol-Foo M. Effect of Maalox (Rm) on the bioavailability of gemifloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 133 (plus poster), Jul 1999Google Scholar
  21. 21.
    Allen A, Vousden M, Porter A, Lewis A. Effect of Maalox (Rm) on the bioavailability of oral gemifloxacin in healthy volunteers. Chemotherapy (Basel) 45: 504–511, Nov–Dec 1999Google Scholar
  22. 22.
    Lode H, Per-Petzold-Bradley P, Lubasch A, Smith A, Lewis A. Effect of calcium carbonate on the bioavailability of gemifloxacin in healthy volunteers. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 38 (plus poster), 17 Sep 2000Google Scholar
  23. 23.
    Allen A, Vousden M, Lewis A. Effect of omeprazole on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Chemotherapy (Basel) 45: 496–503, Nov–Dec 1999Google Scholar
  24. 24.
    Davy M, Allen A, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 133 (plus poster), Jul 1999Google Scholar
  25. 25.
    Davy M, Allen A, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacokinetics of theophylline in healthy volunteers. Chemotherapy (Basel) 45: 478–484, Nov–Dec 1999Google Scholar
  26. 26.
    Nussenblatt RB, de Smet MD, Rubin B, et al. A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. American Journal of Ophthalmology 115: 583–591, 15 May 1993PubMedGoogle Scholar
  27. 27.
    Allen A, Bird N, Dixon R, Hickmott F, Pay V, et al. Effect of cimetidine on the pharmacokinetics of oral gemifloxacin in healthy volunteers. Clinical Drug Investigation 21: 519–526, No. 7, 2001CrossRefGoogle Scholar
  28. 28.
    Oh J-I, Baek K-S, Kim M-Y, Seo M-K, Lee Y-H, et al. In vitro and in vivo antibacterial activities of LB20304, a new fluoronaphthyridone. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 148, 17 Sep 1995Google Scholar
  29. 29.
    Lewandowski T, Berry V, DeMarsh P, Page R, Straub R, et al. In vivo activity of gemifloxacin (SB-265805) in an infant rat meningitis model with Streptococcus pneumoniae. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: 82 (plus poster), 26 Sep 1999Google Scholar
  30. 30.
    Berry V, Page R, Satterfield J, Singley C, Straub R, et al. Comparative efficacy of gemifloxacin (SB-265805) against experimental respiratory tract infection in rats caused by ciprofloxacin-resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 76 (plus poster), 26 Sep 1999Google Scholar
  31. 31.
    Smirnov A, Wellmer A, Gerber K, Maier K, Henne S, et al. Gemifloxacin is effective in experimental pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 44: 767–770, Mar 2000PubMedCrossRefGoogle Scholar
  32. 32.
    Ferguson J, Richards J, Vousden M, Bird N. The low phototoxic potential of gemifloxacin in healthy volunteers. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 144 (plus poster), Jul 1999Google Scholar
  33. 33.
    Barker PJ, Sheehan R, Teillol-Foo M, Palmgren AC, Nord CE. Effect of gemifloxacin on the normal human intestinal microflora. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 279 (plus poster), 26 Sep 1999Google Scholar
  34. 34.
    Kim YK, Choi H, Kim SH, et al. Synthesis and antibacterial activities of LB20304: a new fluoronaphthyridone antibiotic containing novel oxime functionalized pyrrolidine. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 148, 17 Sep 1995Google Scholar
  35. 35.
    Kim M-Y, Oh J-I, Paek K-S, Hong CY, Kim I-C, et al. In vitro activities of LB20304, a new fluoroquinolone. Archives of Pharmacal Research 19: 52–59, Feb 1996CrossRefGoogle Scholar
  36. 36.
    Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrobial Agents and Chemotherapy 41: 204–211, Jan 1997PubMedGoogle Scholar
  37. 37.
    Kelly L, Hoellman D, Bajaksouzian S, Zilles A, Jacobs M, et al. SB-265805 (LB 20304a): activity compared to 11 drugs against Haemophilus influenzae and Moraxella catarrhalis. Clinical Microbiology and Infection 5 (Suppl 3): 143–144, Mar 1999Google Scholar
  38. 38.
    Rittenhouse S, Donald B, Niconovich N, Broskey J, Coleman K. Effect of gemifloxacin and comparator quinolones on the development of in vitro bacterial resistance. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 147 (plus poster), Jul 1999Google Scholar
  39. 39.
    Felmingham D, Robbins MJ, Dencer C, Salman H, Mathias I, et al. In vitro activity of gemifloxacin against S. pneumoniae, H. influenzae, M. catarrhalis, L. pneumophila and Chlamydia spp. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 131 (plus poster), Jul 1999Google Scholar
  40. 40.
    Boswell FJ, Andrews JM, Wise R. The comparative in vitro activity of gemifloxacin, a novel fluoroquinolone. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 132 (plus poster), Jul 1999Google Scholar
  41. 41.
    Rittenhouse S, McCloskey L, Niconovich N, Broskey J, Butler D, et al. Antibacterial activity of gemifloxacin and 14 comparator compounds against 895 Gram-negative clinical isolates. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: 278 (plus poster), 26 Sep 1999Google Scholar
  42. 42.
    Entenza JM, Que YA, Cottagnoud P, Giddey M, Glauser MP, et al. In vitro activity of gemifloxacin (SB-265805) and seven other quinolones against Streptococcus pneumoniae containing specific mutations in the topoisomerase IV (parC) and gyrase (gryA) genes. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 264 (plus poster), 26 Sep 1999Google Scholar
  43. 43.
    Goldstein EJC, Citron DM, Warren Y, Tyrrell K, Merriam CV. In vitro activity of gemifloxacin (SB 265805) against anaerobes. Antimicrobial Agents and Chemotherapy 43: 2231–2235, Sep 1999PubMedGoogle Scholar
  44. 44.
    Davies TA, Kelly LM, Hoellman DB, Ednie LM, Clark CL, et al. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrobial Agents and Chemotherapy 44: 633–639, Mar 2000PubMedCrossRefGoogle Scholar
  45. 45.
    Roblin PM, Reznik T, Kutlin A, Hammerschlag MR. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 43: 2806–2807, Nov 1999PubMedGoogle Scholar
  46. 46.
    Pankuch GA, Kelly LM, Jacobs MR, Appelbaum PC. Antipneumococcal activity of SB 265805 (LB 20304a) (a new broad-spectrum quinolone) compared to nine compounds. Clinical Microbiology and Infection 5 (Suppl 3): 144, Mar 1999Google Scholar
  47. 47.
    Fuentes F, Marco F, Giménez MJ, et al. Comparative in vitro activity of gemifloxacin against S. pneumoniae clinical isolates exhibiting high ciprofloxacin MICs. Journal of Antimicrobial Chemotherapy 44 (Suppl A): 125–126 (plus poster), Jul 1999Google Scholar
  48. 48.
    Felmingham D, Grüneberg RN, Alexander Project Group. The Alexander Project 2000: European surveillance data. Journal of Antimicrobial Chemotherapy 47 (Suppl S1): 24–25, Jun 2001Google Scholar
  49. 49.
    McGee L, Padayachee T, Goldsmith C, Ambler J, Klugman KP. Development of fluoroquinolone resistance amongst pandemic clones of multi-drug-resistant S. pneumoniae: retained activity of gemifloxacin. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 268 (plus poster), 26 Sep 1999Google Scholar
  50. 50.
    Naber CK, Hammer M, Kinzig-Schippers M, Sauber C, Sörgel F, et al. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers. Antimicrobial Agents and Chemotherapy 45: 3524–3530, Dec 2001PubMedCrossRefGoogle Scholar
  51. 51.
    Ball P, Wilson R, Mandell L, File T, Globe Study Group, et al. Gemifloxacin long-term outcomes in bronchitis exacerbations (GLOBE) study — an assessment of health outcome benefits in AECB patients following 5 days gemifloxacin therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy 475 (plus poster), 17 Sep 2000Google Scholar
  52. 52.
    File Jr TM, Schlemmer B, Garau J, Cupo M, 049 Clinical Study Group, et al. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. Journal of Antimicrobial Chemotherapy 48: 67–74, Jul 2001PubMedCrossRefGoogle Scholar
  53. 53.
    Lode H, File T, Mandell L, Ball P, 185 Gemifloxacin Study Group. Comparative efficacy of oral gemifloxacin and IV ceftriaxone followed by oral cefuroxime (plus/minus macrolide) in the treatment of community-acquired pneumonia. Chest 120 (Suppl): 236, Oct 2001Google Scholar
  54. 54.
    Ferguson BJ, Anon JB, Hendrick KC, Hende L, Gemifloxacin 009 Study Group, et al. Efficacy of once daily gemifloxacin for 7 days compared with cefuroxime twice daily for 10 days in the treatment of acute bacterial sinusitis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy: 475 (plus poster), 17 Sep 2000Google Scholar
  55. 55.
    Anon JB, Seltzer EG, Baran C, Weich-Jung C, Gemifloxacin 186 Study Group, et al. Effective 5-day, short-course gemifloxacin therapy of acute bacterial sinusitis. Annals of Allergy, Asthma & Immunology 86: 136, Jan 2001Google Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations